09/06/23 7:00 AMNasdaq : AVIR conferencesAtea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management teamRHEA-AIvery negative
08/08/23 4:05 PMNasdaq : AVIR earningsAtea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateEnrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environment Enrollment continues in Phase 2 trial evaluatingRHEA-AIneutral
08/01/23 7:00 AMNasdaq : AVIR conferencesearningsAtea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call andRHEA-AIneutral
06/15/23 7:00 AMNasdaq : AVIR clinical trialAtea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir CombinationAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery andRHEA-AIneutral
06/05/23 4:20 PMNasdaq : AVIR conferencesAtea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, ChiefRHEA-AIvery negative
05/30/23 7:00 AMNasdaq : AVIR managementAtea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviralRHEA-AIneutral
05/23/23 4:05 PMNasdaq : AVIR Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus aRHEA-AIneutral
05/08/23 4:05 PMNasdaq : AVIR earningsAtea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobal Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV on track for first patient dosed 2Q23;RHEA-AIneutral
05/01/23 4:05 PMNasdaq : AVIR conferencesearningsAtea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call andRHEA-AIneutral
04/25/23 7:00 AMNasdaq : AVIR covid-19Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the United States Food and DrugRHEA-AIneutral